Current Report Filing (8-k)
June 09 2022 - 4:32PM
Edgar (US Regulatory)
0001444307
false
0001444307
2022-06-09
2022-06-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 9, 2022
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
|
|
|
|
|
24 North Main Street,
Pennington, NJ |
|
|
|
08534-2218 |
(Address of Principal Executive
Offices) |
|
|
|
(Zip Code) |
Registrant’s
telephone number, including area code: (855) 662-6732
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol |
|
Name
of each exchange on which registered |
Common Stock, par value
$0.0001 per share |
|
ONCS |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
As
previously disclosed, on December 8, 2021, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”)
from the Nasdaq Stock Market LLC (“Nasdaq”) noting the Company, as a result
of the resignation of Robert E. Ward from the Company’s Board of Directors (the “Board”) and its Audit Committee, no
longer complied with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the Company’s Audit Committee be comprised of at least
three directors, all of whom are independent pursuant to the rules of Nasdaq and applicable law. The Notice also acknowledged that the
Nasdaq Listing Rules provide a cure period in order for the Company to regain compliance until the earlier of the Company’s next
annual meeting of stockholders or November 23, 2022.
On
June 9, 2022, the Company’s Board of Directors appointed director Joon Kim, a current independent member of the Board, to the Audit
Committee. With Mr. Kim’s appointment, the Company has regained compliance with Nasdaq Listing Rule 5605.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: June 9, 2022 |
OncoSec Medical Incorporated |
|
|
|
|
By: |
/s/
Robert H. Arch |
|
Name: |
Robert H. Arch |
|
Title: |
President and Chief Executive Officer |
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024